Cargando…
The Risk of Congenital Heart Anomalies Following Prenatal Exposure to Serotonin Reuptake Inhibitors—Is Pharmacogenetics the Key?
Serotonin reuptake inhibitors (SRIs) are often prescribed during pregnancy. Previous studies that found an increased risk of congenital anomalies, particularly congenital heart anomalies (CHA), with SRI use during pregnancy have created concern among pregnant women and healthcare professionals about...
Autores principales: | Daud, Aizati N. A., Bergman, Jorieke E. H., Kerstjens-Frederikse, Wilhelmina S., Groen, Henk, Wilffert, Bob |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5000730/ https://www.ncbi.nlm.nih.gov/pubmed/27529241 http://dx.doi.org/10.3390/ijms17081333 |
Ejemplares similares
-
Maternal use of drug substrates of placental transporters and the effect of transporter-mediated drug interactions on the risk of congenital anomalies
por: Daud, Aizati N. A., et al.
Publicado: (2017) -
Knowledge and attitude regarding pharmacogenetics among formerly pregnant women in the Netherlands and their interest in pharmacogenetic research
por: Daud, Aizati N. A., et al.
Publicado: (2017) -
P-Glycoprotein-Mediated Drug Interactions in Pregnancy and Changes in the Risk of Congenital Anomalies: A Case-Reference Study
por: Daud, Aizati N. A., et al.
Publicado: (2015) -
Impact of Muscarinic M(3) Receptor Antagonism on the Risk of Type 2 Diabetes in Antidepressant-Treated Patients: A Case-Controlled Study
por: Tran, Yen-Hao, et al.
Publicado: (2017) -
Prenatal exposure to serotonin reuptake inhibitors: a case report
por: Marsella, Maria, et al.
Publicado: (2010)